Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.63 |
| ▸ | F3 | P13726 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | USP7 | Q93009 | 1/20 | 0.58 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | TOP2A | P11388 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883003 | 0.93 | PTPN1 (0.66) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL1050527 | 0.92 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL15132632 | 0.92 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL30222071 | 0.92 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL4324523 | 0.92 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL19360132 | 0.91 | PTPN1 (0.79) | PTPN1ALOX5F3USP2CYP3A4 | |
| SCHEMBL18407010 | 0.89 | PTPN1 (0.58) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL1046309 | 0.88 | PTPN1 (0.83) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL30893653 | 0.88 | PTPN1 (0.83) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL25722752 | 0.88 | PTPN1 (0.57) | PTPN1ALOX5F3USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159436-A1 | APPLICATIONS OF AMIDE ANALOGS OF TRITERPENES IN CURES OF CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20170267714-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170022246-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LTD (CN) | 2017-01-26 | — | — | US | disclosed |
| US-20120277308-A1 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | PACIFIC ARROW LIMITED (CN) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022246-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | VCAM1, EPCAM, ICAM1 | PTPN1 2251/4885ALOX5 252/4885F3 683/4885 |
| US-20120277308-A1 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | TEK, VCAM1, EPCAM | PTPN1 1667/4885ALOX5 251/4885F3 379/4885 |
| US-20230159436-A1 | APPLICATIONS OF AMIDE ANALOGS OF TRITERPENES IN CURES OF CANCER AND OTHER DISEASES | UACA, BRDT, FLT3 | PTPN1 3361/4885ALOX5 250/4885F3 1942/4885 |
| US-20170267714-A1 | NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES | VCAM1, EPCAM, ICAM1 | PTPN1 2251/4885ALOX5 252/4885F3 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.